Welcome to our dedicated page for AC Immune news (Ticker: ACIU), a resource for investors and traders seeking the latest updates and insights on AC Immune stock.
AC Immune SA develops precision therapeutics and diagnostics for neurodegenerative diseases driven by misfolded proteins. The clinical-stage biopharmaceutical company uses its SupraAntigen® and Morphomer® platforms to advance active immunotherapies, small molecules, antibodies, vaccines and diagnostic programs for Alzheimer’s disease, Parkinson’s disease and NeuroOrphan indications.
Company news commonly covers clinical updates for ACI-24 in the ABATE Alzheimer’s disease study, ACI-7104.056 in the VacSYn Parkinson’s disease trial, ACI-19764 as an NLRP3 inflammasome inhibitor, and Tau Morphomer® small-molecule programs. Updates also include collaboration activity with global pharmaceutical partners, milestone payments, symposium presentations, financial results and cash runway disclosures.
AC Immune (NASDAQ: ACIU) will host an industry symposium on Parkinson’s disease and present a first-in-class TDP-43 PET-tracer at AD/PD™ 2026 in Copenhagen, March 17–21, 2026. The symposium on March 18 highlights a precision prevention approach and features data updates, scientific talks, and a Q&A session.
Oral presentation of [18F]ACI-19626 is scheduled for March 19, focusing on biomarker pathways linking amyloid, tau, and neurodegeneration. A symposium replay will be available on the company events page.
AC Immune (NASDAQ: ACIU) has dosed the first participant in a Phase 1 trial of ACI-19764, an oral, brain-penetrant NLRP3 inhibitor. The study in healthy volunteers will assess safety, tolerability, PK/PD, and target engagement, with initial Phase 1 data expected in H2 2026.
Preclinical results reportedly show high potency, CNS penetrance, and reduced neuroinflammation in vivo, positioning ACI-19764 as a competitive candidate for neurodegenerative and inflammatory indications.
AC Immune (NASDAQ: ACIU) reported positive interim Phase 2 VacSYn results for its active immunotherapy ACI-7104.056 in early Parkinson’s disease on December 11, 2025. Part 1 (34 patients, randomized 3:1) reached all immunogenicity targets with a 100% responder rate and serum/CSF antibody titers >500-fold versus placebo. Biomarkers showed stabilization: total CSF a-syn (post-hoc p=0.018), CSF NfL, plasma GFAP trends, and DaT SPECT signals. MDS-UPDRS Part III scores suggested motor stabilization. Safety was favorable with no drug-related serious AEs; most common AEs were injection site reactions (56%), headache (15%), fatigue (12%). Final Part 1 data expected mid-2026.
AC Immune (NASDAQ: ACIU) will participate in the Jefferies 2025 London Healthcare Conference, November 17-20, 2025.
Management will take part in a fireside chat on November 18, 2025 at 4:30 AM ET / 9:30 AM GMT and will hold one-on-one investor meetings. A live webcast of the fireside chat will be available on the company Events Page, and a replay will be archived there. Investors should contact their Jefferies representative to request meetings with management during the conference.
AC Immune (NASDAQ: ACIU) reported Q3 2025 results and a corporate update on November 4, 2025. The company holds CHF 108.5 million in cash resources as of September 30, 2025 (CHF 27.7M cash and CHF 80.7M short-term assets) and said this provides funding to the end of Q3 2027 excluding milestone income. Management narrowed investment focus to three Phase 2 active immunotherapies and small-molecule programs (NLRP3, Tau, a-syn), reduced workforce by ~30%, and recognized CHF 0.5M restructuring expenses.
Near-term milestones expected in Q4 2025 include IND/CTA filing for ACI-19764, lead declarations and IND-enabling starts for Morphomer programs, and multiple Phase 1/2 readouts and interim Part 1 VacSYn results.
AC Immune (NASDAQ: ACIU) appointed Prof. Catherine Mummery as Chair of its Clinical Advisory Board effective October 28, 2025.
Prof. Mummery leads cognitive disorders at NHNN and novel therapeutics at UCL, has been senior investigator on more than 20 early-stage studies, led the first clinical trial of a Tau gene‑silencing therapy, and served as an investigator on AC Immune’s Phase 1b/2a ACI-35.030 (JNJ-2056) study.
The CAB advises on clinical development and regulatory strategy; other members include Reisa Sperling, Murat Emre, Lon Schneider, Pierre Tariot, and Juan Fortea. Dr. Kaj Blennow is retiring from the CAB.
AC Immune (NASDAQ: ACIU) announced that preclinical data for its first-in-class TDP-43 PET tracer ACI-19626 were published in Nature Communications (2025). The report shows high affinity and selectivity for pathological TDP-43 over Abeta, tau and alpha-synuclein, no off-target binding across a panel of >100 targets, and a non-human primate pharmacokinetic profile with rapid brain uptake and fast, complete washout. Based on these data, ACI-19626 advanced into a Phase 1 clinical trial with an initial readout expected in Q4 2025. The tracer aims to enable PET-based diagnosis and patient stratification for TDP-43 proteinopathies including ALS, FTD and LATE.
AC Immune (NASDAQ: ACIU) announced the peer-reviewed publication of Phase 1b/2a trial results for its anti-pTau active immunotherapy in eBioMedicine. The study compared two formulations: ACI-35.030 and JACI-35.054 in early Alzheimer's disease patients.
Key findings showed that ACI-35.030, developed using AC Immune's SupraAntigen® technology, demonstrated superior performance by generating rapid and potent polyclonal response against pathological Tau forms after a single dose. The treatment maintained 94-100% response rates through week 74 in high-dose cohorts, with no clinically relevant safety concerns.
Based on these positive results, ACI-35.030 has advanced to a potentially registration-enabling Phase 2b ReTain clinical trial in preclinical Alzheimer's disease, becoming the first active immunotherapy targeting Tau to be investigated in approximately 500 participants.
AC Immune (NASDAQ: ACIU) has announced a strategic restructuring to optimize its pipeline focus and extend its cash runway. The company will implement a 30% workforce reduction while concentrating on its three clinical-stage active immunotherapy programs and key small molecule programs targeting NLRP3 and Tau.
The restructuring will extend the company's cash runway through Q3 2027, supported by current cash resources of CHF 127.1 million as of June 30, 2025. The company maintains its clinical timeline guidance, with interim data expected from ACI-7104.056 in H2 2025 and ACI-24.060 in H1 2026.
The implementation will be completed by the end of 2025, with cost reductions becoming fully effective in early 2026. Affected employees will receive severance packages and support for new employment opportunities.
AC Immune (NASDAQ: ACIU) reported Q2 2025 financial results and provided updates on its neurodegenerative disease pipeline. The company maintains a strong financial position with CHF 127.1 million in cash, providing runway into Q1 2027. Key highlights include positive interim results from the Phase 2 VacSYn trial of ACI-7104.056 for Parkinson's disease, showing a 20-fold increase in anti-α-syn antibodies.
The company has three active immunotherapies in Phase 2 development, including ACI-24.060 for Alzheimer's disease, with interim results expected in early 2026. Their NLRP3 inhibitor program (ACI-19764) has advanced to IND-enabling studies. Q2 financial results showed contract revenues of CHF 1.3 million and a net loss of CHF 21.2 million, improved from CHF 22.8 million in Q2 2024.